What Is Entresto?

Entresto combines two active ingredients that approach heart failure from different directions:

• Sacubitril inhibits an enzyme called neprilysin. This increases the activity of substances that encourage blood-vessel relaxation, sodium removal, and fluid balance.
• Valsartan is an angiotensin II receptor blocker, commonly shortened to ARB. It blocks signals that tighten blood vessels and promote fluid retention.

Together, these actions can reduce the workload on the heart, lower pressure inside the cardiovascular system, and help the body manage excess sodium and fluid. Entresto controls heart failure rather than curing it, so people are generally instructed to continue taking it even when symptoms improve.

Why is Entresto considered important?

In the landmark PARADIGM-HF trial, sacubitril/valsartan was compared with the ACE inhibitor enalapril in people with heart failure and reduced ejection fraction. Entresto reduced the combined risk of cardiovascular death or first heart-failure hospitalization, with events occurring in 21.8% of the Entresto group and 26.5% of the enalapril group. The relative risk reduction for that combined outcome was approximately 20%.

Current U.S. heart-failure guidance places an ARNI among the foundational treatments for eligible patients with heart failure with reduced ejection fraction, commonly called HFrEF. It is usually part of a broader treatment plan rather than a lone superhero wearing a tiny pharmaceutical cape. Other foundational therapies may include an evidence-based beta blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor.

What Is Entresto Used For?

Chronic heart failure in adults

Entresto is FDA-approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure. Its benefits are most clearly demonstrated in people whose left ventricular ejection fraction is below normal, although clinicians consider the entire medical picture rather than treating one echocardiogram number as a magic password.

Heart failure in children

Entresto is also used for symptomatic heart failure with systemic left ventricular systolic dysfunction in children aged 1 year and older. Pediatric doses are based on weight and may be given as tablets, pharmacist-prepared liquid, or oral pellets sprinkled on a small amount of soft food. Pediatric treatment and dose adjustments require specialist supervision.

Is Entresto a blood pressure medicine?

Its ingredients affect blood pressure, and low blood pressure is a common side effect. However, Entresto is prescribed primarily as a heart-failure medication, not simply as routine hypertension treatment. A lower blood pressure may be part of its effect, but the goal is improved heart-failure outcomesnot winning a contest for the smallest number on the monitor.

Entresto Dosage and How to Take It

Typical adult dosage

The standard recommended starting dose for adults is 49 mg sacubitril/51 mg valsartan twice daily. When tolerated, the dose is generally doubled after two to four weeks to the target maintenance dose of 97 mg/103 mg twice daily. Tablets may be taken with or without food, ideally at approximately the same times each day.

A lower starting dose, usually 24 mg/26 mg twice daily, may be selected for someone who is not currently taking an ACE inhibitor or ARB, previously used only a low dose, has severe kidney impairment, or has moderate liver impairment. No initial adjustment is generally required for mild or moderate kidney impairment, while Entresto is not recommended in severe liver impairment.

The 36-hour ACE inhibitor rule

An ACE inhibitor and Entresto must not be taken together. At least 36 hours must pass when switching between Entresto and an ACE inhibitor such as lisinopril, enalapril, ramipril, or benazepril. This washout reduces the risk of angioedema, a potentially dangerous swelling reaction. Entresto already contains an ARB, so an additional ARB should not normally be added either.

What if you miss a dose?

Take the missed dose when remembered unless it is almost time for the next scheduled dose. In that case, skip it and resume the regular schedule. Do not double the next dose. A pill organizer or phone reminder can prevent the familiar “Did I take it, or did I only think very confidently about taking it?” dilemma.

Common Entresto Side Effects

Not everyone experiences side effects, and some symptoms ease as the body adjusts. In the PARADIGM-HF trial, adverse reactions reported in at least 5% of Entresto-treated patients included:

• Low blood pressure: 18%
• High potassium: 12%
• Cough: 9%
• Dizziness: 6%
• Kidney failure or acute kidney injury: 5%

These percentages come from a controlled clinical trial and do not predict exactly what will happen to a particular patient. Trial participants are monitored closely, and real-world patients may have different ages, illnesses, medications, and tolerances.

Low blood pressure and dizziness

Entresto can cause dizziness, lightheadedness, weakness, or fainting, particularly after treatment begins or the dose increases. Dehydration, vomiting, diarrhea, heavy sweating, low sodium intake, and high diuretic doses can increase the risk. Standing up slowly and reporting repeated dizzy spells can help prevent falls and awkward encounters with nearby furniture.

High potassium

Valsartan affects the renin-angiotensin-aldosterone system and may raise potassium levels. The risk can be greater in people with kidney disease, diabetes, or other conditions that affect potassium balance. Symptoms of severe hyperkalemia may include muscle weakness, unusual heart rhythms, or palpitations, although elevated potassium may produce no obvious warning signs. Periodic blood testing is therefore essential.

Changes in kidney function

Entresto may increase creatinine or worsen kidney function in susceptible patients. Clinicians typically check kidney function before treatment and after starting or increasing the dose. A small laboratory change does not always require stopping therapy, but a significant decline may lead to dose reduction, temporary interruption, or changes to other medications.

Serious Side Effects and Warnings

Angioedema

Swelling of the face, lips, tongue, or throat may signal angioedema. Difficulty breathing or swallowing is a medical emergency. Entresto must be discontinued if angioedema occurs and should not be restarted after a confirmed reaction. It is contraindicated in people with a history of angioedema caused by an ACE inhibitor or ARB and should not be used in hereditary angioedema.

Pregnancy and breastfeeding

Entresto carries an FDA boxed warning for fetal toxicity. It can injure or kill a developing fetus and should be stopped as soon as pregnancy is detected under medical guidance. People who may become pregnant should discuss contraception and pregnancy plans with their clinician before treatment. Breastfeeding is not recommended during therapy.

Who should not take Entresto?

Entresto is contraindicated in people with hypersensitivity to one of its components, previous ACE inhibitor- or ARB-related angioedema, concurrent ACE inhibitor treatment, or concurrent aliskiren use in patients with diabetes. Additional caution may be needed with severe kidney disease, renal artery stenosis, low blood pressure, dehydration, or significant liver disease.

Entresto Drug and Supplement Interactions

Provide the prescriber and pharmacist with a complete list of prescriptions, over-the-counter products, vitamins, supplements, and salt substitutes. Important interactions include:

• ACE inhibitors: Must not be combined with Entresto or taken within the 36-hour washout period.
• Other ARBs: Usually avoided because Entresto already contains valsartan.
• Aliskiren: Contraindicated with Entresto in people with diabetes and generally avoided in significant kidney impairment.
• Potassium supplements and potassium-based salt substitutes: May increase the risk of hyperkalemia.
• Potassium-sparing diuretics: Medicines such as spironolactone, eplerenone, amiloride, or triamterene may require closer potassium monitoring.
• NSAID pain relievers: Ibuprofen, naproxen, and similar drugs may worsen kidney function, especially in older, dehydrated, or diuretic-treated patients.
• Lithium: Entresto may contribute to increased lithium concentrations and toxicity.

These interactions do not always mean two medications can never be used together. They may instead require dose changes, laboratory monitoring, or a deliberate risk-benefit decision. The main rule is refreshingly simple: do not surprise your pharmacist.

How Much Does Entresto Cost?

Entresto cost depends on whether the prescription is filled as the brand or generic product, the dose, pharmacy, insurance plan, deductible, formulary tier, prior-authorization requirements, and eligibility for financial assistance. The amount paid by an insurer is not necessarily the amount charged to the patient.

Medicare pricing in 2026

Under the Medicare Drug Price Negotiation Program, the negotiated maximum fair price for a 30-day supply of Entresto became $295 in 2026, compared with the referenced 2023 list price of $628. That figure governs the price made available within the Medicare program; it is not a guarantee that every beneficiary will pay $295 at the pharmacy counter. Individual costs still depend on plan design, coverage stage, and other Medicare rules.

Is generic Entresto available?

The FDA has approved generic sacubitril/valsartan products, and generic versions may now be dispensed in the United States. Actual stock, manufacturers, insurance preference, and savings vary by pharmacy and region. Patients should verify that an online seller is a legitimate licensed pharmacy rather than assuming that a suspiciously cheap website has suddenly developed a generous heart.

Ways to reduce the cost

• Ask whether the insurance plan prefers generic sacubitril/valsartan or brand-name Entresto.
• Request a formulary exception or prior authorization when clinically appropriate.
• Compare prices at nearby licensed pharmacies.
• Ask whether a 90-day supply or mail-order pharmacy lowers the per-month cost.
• Review Medicare Extra Help eligibility when applicable.
• Contact the manufacturer’s patient-support service for current eligibility rules.

Manufacturer copay support may be available to eligible people with commercial insurance, but program terms can change and assistance is generally not valid for Medicare, Medicaid, TRICARE, VA, or other government-funded coverage.

Alternatives to Entresto

There is no perfect one-size-fits-all replacement. The best alternative depends on ejection fraction, blood pressure, kidney function, potassium level, previous angioedema, pregnancy status, symptoms, insurance coverage, and which other heart-failure treatments are already being used.

ACE inhibitors

Medicines such as enalapril, lisinopril, ramipril, and captopril may be used when an ARNI is unsuitable or inaccessible. ACE inhibitors can improve outcomes in HFrEF, but they must never overlap with Entresto, and the required 36-hour washout applies when switching. They can also cause cough, high potassium, kidney-function changes, low blood pressure, angioedema, and fetal harm.

Angiotensin receptor blockers

Valsartan, candesartan, or losartan may be considered when an ACE inhibitor causes cough or is otherwise unsuitable and Entresto cannot be used. ARBs should not be taken alongside Entresto because valsartan is already one of its ingredients.

Hydralazine and isosorbide dinitrate

This combination may be considered in selected patients who cannot take an ARNI, ACE inhibitor, or ARB because of intolerance or kidney-related concerns. It also has an established role in certain Black patients with persistent symptomatic HFrEF despite appropriate guideline-directed therapy. Headache, dizziness, low blood pressure, and a demanding dosing schedule may affect tolerability.

Medicines that complement rather than replace Entresto

Beta blockers such as carvedilol, metoprolol succinate, or bisoprolol; mineralocorticoid receptor antagonists such as spironolactone or eplerenone; and SGLT2 inhibitors such as dapagliflozin or empagliflozin are often used alongside Entresto. Loop diuretics such as furosemide may relieve fluid congestion but do not replace the long-term outcome benefits of foundational HFrEF therapy.

What Should Be Monitored During Treatment?

Monitoring commonly includes blood pressure, kidney function, potassium, symptoms, body weight, swelling, breathing, and medication tolerance. Some people are asked to record their morning weight and contact the heart-failure team after a rapid increase, since sudden weight gain may indicate fluid retention rather than a spontaneous overnight career in competitive bodybuilding.

Seek prompt medical guidance for fainting, severe dizziness, reduced urination, persistent vomiting or diarrhea, worsening shortness of breath, rapidly increasing swelling, palpitations, or unusual weakness. Call emergency services for facial or throat swelling, severe trouble breathing, collapse, or other life-threatening symptoms.

Experiences With Entresto: What Day-to-Day Treatment May Feel Like

The following examples are composite educational scenarios, not quotations from specific patients and not predictions of how any one person will respond.

The first few weeks may involve adjustment

A common experience begins with a low or standard starting dose, followed by a check of blood pressure, creatinine, and potassium. Someone who previously tolerated lisinopril or losartan may expect the transition to be uneventful, then notice mild dizziness during the first several mornings. The practical response is not usually to abandon treatment after breakfast. The clinician may review fluid intake, diuretic dosage, blood pressure readings, and whether the person is standing up too quickly.

Some patients feel little or no immediate difference. That can be confusing because people often expect an important medicine to announce its arrival with dramatic music and a burst of energy. Entresto’s main value is reducing future cardiovascular events and hospitalizations; it may not create an obvious daily sensation. Improvements in breathing, exercise tolerance, swelling, or fatigue may occur gradually and can be difficult to separate from the effects of other heart-failure therapies.

Dose increases can restart the learning curve

After two to four weeks, the clinician may increase the dose toward 97/103 mg twice daily. A person who felt perfectly comfortable at the lower dose might experience renewed lightheadedness after titration. Home blood pressure records become useful here. One isolated lower reading without symptoms may be handled differently from repeated readings accompanied by weakness, falls, or near-fainting.

Laboratory testing can also uncover high potassium or a creatinine increase before the patient feels anything unusual. The solution may involve adjusting potassium supplements, salt substitutes, NSAID use, diuretics, or another heart-failure medicine rather than automatically eliminating Entresto. Treatment is frequently a balancing act, and the balance occasionally needs a spreadsheet.

Medication routines matter

Because Entresto is normally taken twice daily, consistency can be harder than with a once-daily pill. Patients often connect each dose with an established routine, such as breakfast and brushing their teeth before bed. A medication box, alarm, or refill reminder can help prevent missed doses.

Refill logistics can become a larger part of the experience than anyone would prefer. Insurance may require prior authorization, substitute generic sacubitril/valsartan, or change the copay at the start of a plan year. Addressing refills one or two weeks before the bottle is empty can leave time for pharmacy stock issues or coverage appeals. Running out and stretching doses without medical advice is unsafe.

Good follow-up can make treatment easier

The smoothest experiences usually involve clear communication. Patients benefit from knowing which blood pressure readings should trigger a call, when laboratory work is due, what to do during vomiting or diarrhea, and which pain relievers or salt substitutes to avoid. Bringing an updated medication list to appointments prevents accidental duplication with an ACE inhibitor or ARB.

Entresto is not effortless treatment, but neither is it necessarily disruptive. For many eligible patients, the routine eventually becomes ordinary: two doses, occasional laboratory tests, daily symptom awareness, and regular cardiology follow-up. In heart-failure care, “ordinary” can be a valuable achievement.

Conclusion

Entresto combines sacubitril and valsartan to reduce the risk of cardiovascular death and heart-failure hospitalization in appropriate patients. It is a foundational treatment for many people with HFrEF, but safe use requires attention to blood pressure, kidney function, potassium, pregnancy risk, drug interactions, and the mandatory 36-hour separation from ACE inhibitors.

The most common concerns are low blood pressure, high potassium, cough, dizziness, and kidney-function changes. Serious facial or throat swelling requires emergency care. Cost may be reduced through generic availability, insurance review, Medicare benefits, pharmacy comparisons, or eligible assistance programs. When Entresto is unsuitable, ACE inhibitors, ARBs, or hydralazine with isosorbide dinitrate may be considered, although the choice should be made by a clinician familiar with the patient’s complete heart-failure plan.